A ngiotensin-converting enzyme (ACE) inhibitors are often used to treat cardiac hypertrophy, 1 a significant cardiovascular risk factor in hypertensive patients. 2 The antihypertrophic action of ACE inhibitors in vivo is abolished by the B 2 -kinin receptor antagonist HOE 140, 3 indicating a significant contribution by bradykinin. In addition, B 2 -kinin receptor deficiency promotes the development of cardiac hypertrophy in vivo, 4 whereas kallikrein overexpression prevents cardiac growth. 5 However, the mechanism by which bradykinin counteracts hypertrophic stimuli in the heart is not fully understood. We have shown that bradykinin prevents hypertrophy of isolated cardiomyocytes by stimulating the release of NO from endothelial cells 6 and that this action is associated with elevation of cardiomyocyte cyclic GMP. 7 An analogue of cyclic GMP, 8-bromo-cyclic GMP, also prevents hypertrophy of isolated rat cardiomyocytes, 8 but whether stimulation of cyclic GMP is essential for the antihypertrophic action of bradykinin has not been addressed.
Cardiomyocyte hypertrophy is characterized by increased protein synthesis and cell size and induction of the immediate early (eg, c-fos, c-jun, and c-myc) and fetal genes (eg, ␤-myosin heavy chain, skeletal ␣-actin, and atrial natriuretic peptide, ANP). 9 These cellular changes are established in vitro markers for cardiomyocyte hypertrophy in neonatal 10 and adult cardiomyocytes, 11 as well as in isolated whole hearts stimulated with mechanical load or neurohumoral factors (eg, norepinephrine or angiotensin II, Ang II). 12, 13 The intact rat heart expresses a functional kallikrein-kinin system, 14 but the antihypertrophic action of bradykinin has not been investigated in this setting, where autocrine/paracrine factors (eg, Ang II, endothelin-1, transforming growth factor-␤ 1 ) may influence cardiac growth at the same time. 15 Our objective was to examine the acute antihypertrophic effect of bradykinin in the rat isolated heart, compared with an ACE inhibitor and nitric oxide (NO) donor, and to examine the contribution of cyclic GMP to the bradykinin response in vitro.
Methods

Materials
Ang II, sodium nitroprusside (SNP), 1H-1,2,4 oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), L -amino acids, bovine serum albumin (BSA, fraction V), and D,L-lactic acid were obtained from Sigma Biochemicals. Bradykinin was from Auspep; ramiprilat and HOE 140 were a gift from Hoechst AG (Frankfurt, Germany). Real time polymerase chain reaction (PCR) reagents were purchased from Applied Biosystems. All other reagents were from Sigma unless otherwise stated. All protocols were approved by the Animal Experimentation Ethics Committee of the Howard Florey Institute.
Isolation of Adult Rat Cardiomyocytes
Male Sprague-Dawley rats (180 to 280 g) were terminally anesthetized by intraperitoneal bolus of ketamine hydrochloride (100 mg/kg) and xylazine (12 mg/kg). Cardiomyocytes were isolated as previously described 7 and resuspended in serum-free medium 199 (M199, Trace Scientific), containing 0.2% BSA, 2 mmol/L L-carnitine, 5 mmol/L creatine, 5 mmol/L taurine, 25 g/mL gentamicin (Life Technologies), 100 U/mL penicillin, and 100 g/mL streptomycin (CSL Biosciences). Cardiomyocytes were plated into laminin (10 g/mL; Collaborative Biomedical Products)-coated 6-well plates and equilibrated at 37°C (5% CO 2 /95% O 2 ) for 2 to 24 hours.
Bovine Aortic Endothelial Cell (BAEC) Cultures
BAEC were isolated as described 16 and maintained at 37°C (5% CO 2 /95% O 2 ) in DMEM (Life Technologies) containing 10% fetal calf serum (CSL Biosciences), 4 mmol/L L-glutamine (Life Technologies), 66 g/mL gentamicin, 650 U/mL penicillin, and 650 g/mL streptomycin (CSL Biosciences). BAEC were grown to confluence on 30-mm tissue-culture inserts (0.4-m membrane, Millipore) and washed in M199 immediately before use. BAEC were used at passages 4 to 6 and at passage 12 in one experiment. No difference in the response to drug treatments was observed at the higher passage.
[ 3 H]Phenylalanine Incorporation by Cardiomyocytes
Cardiomyocytes were incubated with BAEC-coated inserts for 2 hours at 37°C in serum-free M199 containing L-[2,3,4,5-3 H]-phenylalanine (2 Ci/mL, NEN Lifesciences) Ϯ Ang II (1 mol/L) Ϯ bradykinin (10 mol/L) Ϯ ODQ (10 mol/L). Solutions containing bradykinin were supplemented with ramiprilat (1 mol/L) to limit degradation; 17 12 The aorta was cannulated and attached to a modified Langendorff rodent heart perfusion system (Petersen Scientific Glass Blowing Pty Ltd) for retrograde perfusion under constant pressure (60 mm Hg). Heart rate and coronary flow were monitored manually (collection of efflux over 60 seconds) throughout the perfusion. Hearts perfused by this method maintained regular contractions for 2.5 to 3 hours.
Experimental Protocol
Following equilibration (15 minutes), hearts were perfused for 90 minutes with buffer alone or buffer containing study drugs. Ang II (acute hypertrophic stimulus) 12 was added after 30 minutes. Seven groups were studied:
Ramiprilat (10 nmol/L) was added to bradykinin-containing solutions to prevent degradation; 17 
H]Phenylalanine Incorporation by LV Protein
Protein synthesis was determined as previously described. 12 LV tissue (100 to 150 g) was homogenized in 2 mL ice-cold 6% TCA to denature protein and remove unincorporated [ 3 H]phenylalanine. Following centrifugation, pellets were washed in 6% TCA and heated to 80°C for 20 minutes to remove RNA-bound [ 3 H]phenylalanine. After centrifugation, pellets were washed in 6% TCA and resuspended in 0.2 N NaOH. Aliquots were taken for liquid scintillation counting and protein assay by the Lowry method.
ANP mRNA Expression
Total RNA was extracted from LV tissue (30 to 50 mg) using RNAWiz™ (Ambion) and reverse-transcribed to 10 ng/L cDNA concentration using TaqMan ® reverse transcription reagents (Applied Biosystems). 20 ANP mRNA was quantified by real time PCR and the ⌬⌬Ct method with 18S ribosomal RNA as the internal standard. 20, 21 Primers and probes were designed from rat-specific sequences published on GenBank (Table) . Probes were 5Ј-labeled with the reporter dye FAM (ANP) or VIC (18S) and 3Ј-labeled with the quencher molecule carboxytetramethylrhodamine (TAMRA). Optimal primer and probe concentrations were determined in initial studies (Table) . All reactions were performed in the ABI Prism ® 7700 sequence detection system (Applied Biosystems) as described. 20 
LV Cyclic GMP Content
Pieces of LV tissue (Ϸ200 mg) were weighed and homogenized in ice-cold 6% TCA. Following centrifugation, supernatant was extracted in water-saturated diethyl ether and dried under a stream of air at 70°C. The residue was resuspended in sodium acetate assay buffer (0.05 mol/L, pH 6.2), and cyclic GMP content was determined 
Optimal Sequences (533) and Concentrations of Taqman Primers and Probes
Statistical Comparisons
For isolated cell studies, treatment groups were studied at least in triplicate and the average result taken for each experiment; "n" for each set of results represents the number of myocyte preparations studied. 
Results
Cyclic GMP Mediates the Antihypertrophic Action of Bradykinin in Cardiomyocytes
In cardiomyocyte/BAEC cocultures, Ang II-stimulated [ 3 H]phenylalanine incorporation (to 135Ϯ2% of control, PϽ0.001, nϭ6) was abolished by bradykinin (98Ϯ3% of control, nϭ6, Figure 1 ). ODQ prevented the antihypertrophic action of bradykinin (131Ϯ3% of control, PϽ0.05 versus Ang II ϩ bradykinin, nϭ6).
Heart Rate and Coronary Flow in Rat Isolated Hearts
Resting heart rate remained at 181Ϯ8 beats/min in vehicleperfused hearts (nϭ20). Heart rate was not significantly altered by any of the drug treatments (range 165 to 210 beats/min). Coronary flow in vehicle hearts averaged 11.4Ϯ1.0 mL/min (nϭ20). Bradykinin and ramiprilat (before addition of Ang II) tended to increase coronary flow to 12.9Ϯ0.7 (nϭ8, Pϭ0.06) and 14.1Ϯ1.9 mL/min (nϭ8, Pϭ0.07), respectively. Addition of Ang II restored flow to 9.6Ϯ0.9 (nϭ7, PϽ0.05 versus bradykinin alone) and 9.9Ϯ1.1 (nϭ8, Pϭ0.07 versus ramiprilat alone). Ang II alone or in combination with other drug treatments did not alter coronary flow.
Bradykinin Prevents the Acute Hypertrophic Response to Ang II in Whole Hearts
Compared with hearts perfused with vehicle alone, Ang II (10 nmol/L) stimulated LV [ 
In addition to its effects on [
3 H]phenylalanine incorporation, Ang II also significantly increased LV expression of ANP mRNA to 9.4Ϯ4.5-fold above vehicle (PϽ0.05, nϭ8, Figure 4 ). This was completely prevented by bradykinin (1.7Ϯ0.5-fold, nϭ6, PϽ0.05 versus Ang II). A similar protective action against Ang II-induced expression of ANP mRNA was observed with SNP (2.0Ϯ0.6-fold, PϽ0.05 versus Ang II, nϭ9) and ramiprilat (2.7Ϯ1.1-fold of control, nϭ 6, PϽ0.05 versus Ang II, Figure 4 ).
Bradykinin Stimulates Cyclic GMP in the Isolated Perfused Rat Heart
Compared with perfusion with vehicle alone, Ang II exerted negligible effects on cyclic GMP content (118Ϯ15% of vehicle, nϭ12, Figure 5 ). In contrast, bradykinin markedly stimulated cyclic GMP accumulation to 202Ϯ46% of vehicle (nϭ6, PϽ0.05 versus Ang II). Addition of SNP or ramiprilat failed to elevate cyclic GMP significantly (142Ϯ20% and 135Ϯ17% of vehicle, respectively, both nϭ6, Figure 5 ).
Discussion
The key finding to emerge from the present study is that bradykinin exerts a marked antihypertrophic action in the isolated perfused rat heart, which more closely resembles the in vivo setting than do isolated myocytes. This action was mimicked by an ACE inhibitor and an NO donor. Furthermore, the antihypertrophic action of bradykinin was associated with elevation of LV cyclic GMP in whole hearts and was abolished by soluble guanylyl cyclase inhibition in isolated cardiomyocytes. Thus, we demonstrate for the first time that bradykinin elicits a potent, direct, antihypertrophic action in the rat heart and that cyclic GMP appears to be an important mediator of this response.
In the rat isolated heart, Ang II-induced increases in LV [
3 H]phenylalanine incorporation and ANP mRNA expression were abolished by bradykinin and SNP (Figures 2 and 4) . This is in agreement with findings that nitrates can preventing cardiac remodeling and hypertrophy 22 and supports our earlier report that activation of endothelial bradykinin receptors with subsequent release of NO prevents hypertrophy in cardiomyocytes cocultured with endothelial cells. 6 The ACE inhibitor ramiprilat was similarly protective in whole hearts (Figures 3 and 4) and a large component of this effect was sensitive to HOE 140 ( Figure 3) . Thus, bradykinin contributes significantly to the antihypertrophic action of ACE inhibitors in vitro, in accordance with findings in chronic hypertrophy in vivo. 23 Inhibition of endogenous ACE-mediated Ang II production is unlikely to be involved in the present model of acute hypertrophy, because exogenous Ang II was infused as the hypertrophic stimulus. The antihypertrophic action of exogenous bradykinin in the whole heart was accompanied by powerful stimulation of LV cyclic GMP (Figure 5 ), reflecting our earlier reports in cultured cells. 6 Moreover, the soluble guanylyl cyclase inhibitor ODQ abolished the bradykinin effect in cultured cells (Figure 1 ), highlighting the importance of cyclic GMP. The endogenous kallikrein-kinin system is likely to contribute to the regulation of cardiac hypertrophy in vivo, 4, 24 possibly involving activation of NO/cyclic GMP signaling. 25 Specific inhibition of cyclic GMP phosphodiesterase activity has also been shown to prevent hypertrophy of neonatal cardiomyocytes. 26 Thus, cyclic GMP is a key intracellular signal by which bradykinin counteracts hypertrophic stimuli in the rat heart. This action may involve inhibition of mitogen-activated protein kinase cascades 27 or of endothelin-1 expression by cardiac fibroblasts. 15 In addition, regulation of cardiac Ca 2ϩ current through cyclic GMP-gated cation channels 28 may prevent hypertrophic signaling via calcineurin. 29 A recent report suggested that bradykinin may also stimulate cardiac P 2 purinoceptors via ATP, 30 but whether this contributes to the antihypertrophic action of bradykinin in the heart is not known.
In our hands, the antihypertrophic action of ramiprilat was attenuated to a similar degree by both the soluble guanylyl cyclase inhibitor ODQ and the B 2 -kinin receptor antagonist HOE 140 (Figure 2 ), suggesting that elevation of cyclic GMP is a common pathway in the rat heart used by bradykinin, ramiprilat, and possibly, SNP. However, both ramiprilat and SNP failed to induce significant increases in LV cyclic GMP (Figure 4) , despite exerting an acute antihypertrophic effect comparable to bradykinin (Figures 2 and 3) . Although higher concentrations, or the addition of a cyclic GMP phosphodiesterase inhibitor such as zaprinast, might have caused greater elevation of cyclic GMP, amounts of SNP used were higher than previously reported as effective in isolated hearts. 31 It is possible that only small increases in cyclic GMP in the myocyte cytosol are required to suppress hypertrophic sig- naling in the rat heart. Alternatively, additional mechanisms not involving cyclic GMP may contribute. NO has been reported to exert cyclic GMP-independent actions, including oxygen radical scavenging, 31 decreased intracellular Ca 2ϩ , 32 inhibition of endothelial cell proliferation, 33 suppression of mitochondrial metabolism, 34 and direct activation of Ca 2ϩ -dependent K ϩ channels. 35 Furthermore, ACE inhibitors may elicit pleiotropic effects independently of local ACE inhibition 36 through direct regulation of cardiac Na ϩ /K ϩ pump activity 37 or mitogen activated protein kinase signal transduction. 38 One final consideration is that the whole heart is more complex than the isolated cardiomyocyte, and the multiple cell types and messenger systems that are present simultaneously are likely to modulate responses to different antihypertrophic agents. In the present study, any influences on hypertrophic markers and accumulation of cyclic GMP were assumed to be due to direct actions rather than secondary to a vasoactive action of the drug treatments, given that coronary flow varied little with different treatments in the present study. A key advantage of the whole-heart model over isolated myocytes is that findings regarding acute antihypertrophic mechanisms may be more confidently extrapolated to the chronic situation in vivo.
In conclusion, bradykinin prevents the acute hypertrophic response to Ang II in the isolated perfused rat heart, and this effect is accompanied by significant elevation of LV cyclic GMP. Furthermore, the antihypertrophic action of an ACE inhibitor in this system was shown to depend in part on activation of both bradykinin receptors and soluble guanylyl cyclase. Acute antihypertrophic mechanisms studied in the isolated heart thus reflect those reported for longer-term cardioprotection in vivo. We propose that cyclic GMP per se is an important antihypertrophic mechanism in the rat heart, which may be a therapeutic target for the prevention of inappropriate cardiomyocyte enlargement.
Perspectives
Increased cardiomyocyte cyclic GMP is essential for the antihypertrophic actions of bradykinin in the adult rat heart and contributes to the protective effect of ACE inhibitors. These findings may be particularly important in understanding conditions where regulation of soluble guanylyl cyclase is altered, such as in the aging heart, 39 or in diabetes where endothelial NO/cyclic GMP function is compromised. 40 
